Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
08 Abril 2019 - 12:59AM
Sanofi and Alnylam conclude research and option phase of
2014 rare disease alliance
Paris – April 8, 2019 – Sanofi
and Alnylam have agreed to conclude the research and option phase
of the companies’ 2014 RNAi therapeutics alliance in rare genetic
diseases. The material collaboration terms for patisiran,
vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced,
will continue unchanged.
As part of this agreement, Alnylam will advance
an additional investigational asset in an undisclosed rare genetic
disease through the end of IND-enabling studies. Sanofi will be
responsible for any potential further development or
commercialization of such asset. If this product is approved,
Alnylam will be eligible to receive tiered double-digit royalties
on its global net sales.
“Our alliance with Alnylam has successfully
brought one important medicine to patients with ATTR amyloidosis
and it also has spawned a molecule that is in pivotal clinical
trials for people with hemophilia,” said John Reed, Global Head of
Research and Development at Sanofi. “As we wrap up this phase of
our program with Alnylam, we remain committed to advancing
therapies for patients with rare diseases and rare blood
disorders.”
In addition, Alnylam and Sanofi have agreed to
amend certain terms of the companies' equity agreement, with Sanofi
obtaining a release of its lock-up of Alnylam stock holdings,
subject to certain trading restrictions, amongst other
provisions.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions. With
more than 100,000 people in 100 countries, Sanofi is transforming
scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life |
Media Relations
Contact Ashleigh Koss Tel.: +1 908 981 8745
mr@sanofi.com |
Investor
Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45
ir@sanofi.com |
Sanofi Forward-Looking StatementsThis
press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi’s ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2018. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024